Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 13, 2026, 6:42 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 97–120 of 235 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Anticoagulant drugs Clear all
Completed No phase listed Observational

Prediction of the COBRRA VTE Anticoagulant Trial in Healthcare Claims Data

NCT05264168
View directory record Official record
Conditions
Venous Thromboembolism, Pulmonary Embolism, DVT
Interventions
Rivaroxaban, Apixaban
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 120 Years
Enrollment
41,875 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 27, 2023 · Synced Oct 13, 2026, 6:42 PM EDT
Completed Phase 2 Interventional Results available

EINSTEIN Junior Phase II: Oral Rivaroxaban in Young Children With Venous Thrombosis

NCT02309411
View directory record Official record
Conditions
Venous Thromboembolism
Interventions
Rivaroxaban (Xarelto, BAY59-7939)
Drug
Lead sponsor
Bayer
Industry
Eligibility
6 Months to 5 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
5
States / cities
Gainesville, Florida • Pensacola, Florida • Atlanta, Georgia + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 21, 2018 · Synced Oct 13, 2026, 6:42 PM EDT
Terminated Phase 3 Interventional Results available

Rivaroxaban Versus Aspirin in Secondary Prevention of Stroke and Prevention of Systemic Embolism in Patients With Recent Embolic Stroke of Undetermined Source (ESUS)

NCT02313909
View directory record Official record
Conditions
Stroke
Interventions
Rivaroxaban (Xarelto, BAY59-7939), Acetylsalicylic acid (Aspirin, BAY1019036), Rivaroxaban-Placebo, Aspirin-Placebo
Drug · Other
Lead sponsor
Bayer
Industry
Eligibility
50 Years and older
Enrollment
7,213 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
38
States / cities
Tucson, Arizona • Long Beach, California • Stanford, California + 32 more
Source: ClinicalTrials.gov public record
Updated Jan 9, 2019 · Synced Oct 13, 2026, 6:42 PM EDT
Completed Phase 4 Interventional

The Impact of Factor Xa Inhibition on Thrombosis, Platelet Activation, and Endothelial Function in Peripheral Artery Disease

NCT05009862
View directory record Official record
Conditions
Peripheral Arterial Disease
Interventions
Rivaroxaban 2.5 Mg Oral Tablet, Placebo, Aspirin 81Mg Ec Tab
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
40 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jul 14, 2026 · Synced Oct 13, 2026, 6:42 PM EDT
Terminated Phase 3 Interventional Accepts healthy volunteers Results available

Study of Arixtra (Fondaparinux Sodium) to Prevent Blood Clots in Women Undergoing Abdominopelvic Surgery for Likely Gynecologic Malignancy

NCT00539942
View directory record Official record
Conditions
Venous Thrombosis
Interventions
Arixtra (fondaparinux sodium), Intermittent compression devices (ICD)
Drug · Device
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
19 Years to 85 Years · Female only
Enrollment
7 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2010
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Mar 27, 2017 · Synced Oct 13, 2026, 6:42 PM EDT
Completed Not applicable Interventional Results available

Keep it SIMPLE: Improving Anti-Coagulation Medication Adherence

NCT02690649
View directory record Official record
Conditions
Atrial Fibrillation, Medication Adherence
Interventions
Health Messaging (Non-Procedural)
Other
Lead sponsor
Tammy Toscos
Other
Eligibility
18 Years and older
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Fort Wayne, Indiana
Source: ClinicalTrials.gov public record
Updated Oct 28, 2021 · Synced Oct 13, 2026, 6:42 PM EDT
Completed Not applicable Interventional

Using Artificial Intelligence to Measure and Optimize Adherence in Patients on Anticoagulation Therapy.

NCT02599259
View directory record Official record
Conditions
Stroke
Interventions
Monitored (M+)
Device
Lead sponsor
AiCure
Industry
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 12, 2016 · Synced Oct 13, 2026, 6:42 PM EDT
Completed Phase 3 Interventional Results available

A Study in Participants With Acute Major Bleeding to Evaluate the Ability of Andexanet Alfa to Reverse the Anticoagulation Effect of Direct and Indirect Oral Anticoagulants (Extension Study)

NCT02329327
View directory record Official record
Conditions
Bleeding
Interventions
Andexanet
Biological
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
479 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
23
States / cities
Long Beach, California • Los Angeles, California • Orange, California + 20 more
Source: ClinicalTrials.gov public record
Updated Feb 16, 2022 · Synced Oct 13, 2026, 6:42 PM EDT
Completed No phase listed Observational Results available

FlowTriever All-Comer Registry for Patient Safety and Hemodynamics

NCT03761173
View directory record Official record
Conditions
PE - Pulmonary Embolism, PE - Pulmonary Thromboembolism
Interventions
FlowTriever System, Anticoagulation Agents
Device · Drug
Lead sponsor
Inari Medical
Industry
Eligibility
18 Years and older
Enrollment
1,200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
59
States / cities
Birmingham, Alabama • Tucson, Arizona • Aurora, Colorado + 47 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2025 · Synced Oct 13, 2026, 6:42 PM EDT
Completed Not applicable Interventional Results available

Once Weekly Subcutaneous Ports for the Administration of Anticoagulants

NCT00774748
View directory record Official record
Conditions
Venous Thromboembolism
Interventions
Insuflon
Device
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated May 23, 2017 · Synced Oct 13, 2026, 6:42 PM EDT
Terminated Phase 2 Interventional Results available

Efficacy and Safety of Apixaban in the Treatment of Heparin Induced Thrombocytopenia (HIT)

NCT03594045
View directory record Official record
Conditions
Heparin-induced Thrombocytopenia, Heparin-induced Thrombocytopenia and Thrombosis
Interventions
Apixaban
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
3
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 23, 2020 · Synced Oct 13, 2026, 6:42 PM EDT
Completed Phase 4 Interventional Results available

Bone Marrow Aspirate Compared to Platelet Rich Plasma for Treating Knee Osteoarthritis

NCT03289416
View directory record Official record
Conditions
Knee Osteoarthritis
Interventions
Pure PRP II, PureBMC
Combination Product
Lead sponsor
Andrews Research & Education Foundation
Other
Eligibility
18 Years to 80 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2020
U.S. locations
1
States / cities
Gulf Breeze, Florida
Source: ClinicalTrials.gov public record
Updated Apr 20, 2025 · Synced Oct 13, 2026, 6:42 PM EDT
Terminated Phase 2 Interventional Results available

Feasibility Study of Unfractionated Heparin in Acute Chest Syndrome

NCT02098993
View directory record Official record
Conditions
Acute Chest Syndrome, Sickle Cell Disease
Interventions
Unfractionated heparin
Drug
Lead sponsor
Craig Seaman
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 16, 2019 · Synced Oct 13, 2026, 6:42 PM EDT
Terminated Not applicable Interventional Results available

A Prospective, Open Label, Multicenter Trial for Evaluating the Efficacy of Treating and Managing Wounds in Elderly Population in Specialized Nursing Facilities Using RD1

NCT04577183
View directory record Official record
Conditions
Diabetic Foot Ulcer, Pressure Ulcer, Venous Leg Ulcer, Trauma Injury, Skin Tear, Chronic Ulcer
Interventions
RD1 System
Device
Lead sponsor
RedDress Ltd.
Industry
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Butler, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 2, 2024 · Synced Oct 13, 2026, 6:42 PM EDT
Completed Not applicable Interventional

D-dimer to Select Patients With First Unprovoked Venous Thromboembolism Who Can Have Anticoagulants Stopped at 3 Months

NCT00720915
View directory record Official record
Conditions
Deep Vein Thrombosis, Pulmonary Embolism
Interventions
Discontinue anticoagulant therapy (Negative d-dimer), Continue on anticoagulant therapy (positive d-dimer)
Other
Lead sponsor
McMaster University
Other
Eligibility
18 Years to 75 Years
Enrollment
410 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2016
U.S. locations
7
States / cities
Washington D.C., District of Columbia • Iowa City, Iowa • Boston, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Dec 13, 2016 · Synced Oct 13, 2026, 6:42 PM EDT
Not yet recruiting Phase 3 Interventional

Efficacy and Safety of Tenecteplase Among acutE Ischemic Stroke Patients With Recent Ingestion of Direct Oral Anticoagulant

NCT07621796
View directory record Official record
Conditions
Acute Ischemic Stroke
Interventions
Intravenous tenecteplase (TNK), Placebo
Drug
Lead sponsor
Hackensack Meridian Health
Other
Eligibility
18 Years and older
Enrollment
660 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2032
U.S. locations
1
States / cities
Neptune City, New Jersey
Source: ClinicalTrials.gov public record
Updated Jun 2, 2026 · Synced Oct 13, 2026, 6:42 PM EDT
Completed No phase listed Observational

Ischemia Care Biomarkers of Acute Stroke Etiology (BASE)

NCT02014896
View directory record Official record
Conditions
Ischemic Stroke, Atrial Fibrillation, Transient Ischemic Attacks, Transient Cerebrovascular Events, Thrombotic Stroke, Stroke of Basilar Artery, Cardioembolic Stroke
Interventions
Biomarker blood draw
Other
Lead sponsor
Ischemia Care LLC
Industry
Eligibility
18 Years and older
Enrollment
1,750 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2020
U.S. locations
22
States / cities
Sacramento, California • San Francisco, California • Detroit, Michigan + 17 more
Source: ClinicalTrials.gov public record
Updated Jul 8, 2020 · Synced Oct 13, 2026, 6:42 PM EDT
Completed Phase 1 Interventional Results available

Phase 1 Pediatric Pharmacokinetics/Pharmacodynamics (PK/PD) Study

NCT02303431
View directory record Official record
Conditions
Deep Vein Thrombosis, Venous Thromboembolism
Interventions
Edoxaban low dose, Edoxaban high dose
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
0 Years to 18 Years
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
12
States / cities
Los Angeles, California • Palo Alto, California • Denver, Colorado + 9 more
Source: ClinicalTrials.gov public record
Updated Oct 11, 2023 · Synced Oct 13, 2026, 6:42 PM EDT
Completed Phase 3 Interventional Results available

Reversal of Dabigatran Anticoagulant Effect With Idarucizumab

NCT02104947
View directory record Official record
Conditions
Hemorrhage
Interventions
idarucizumab
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
503 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
30
States / cities
Little Rock, Arkansas • Loma Linda, California • Washington D.C., District of Columbia + 25 more
Source: ClinicalTrials.gov public record
Updated Jan 5, 2018 · Synced Oct 13, 2026, 6:42 PM EDT
Completed No phase listed Observational

Prospective Evaluation of Bleeding Risk of Anticoagulant and Anti-platelet Therapy

NCT00625248
View directory record Official record
Conditions
Bleeding
Interventions
Antithrombotics
Drug
Lead sponsor
Pain Management Center of Paducah
Other
Eligibility
18 Years and older
Enrollment
12,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Paducah, Kentucky
Source: ClinicalTrials.gov public record
Updated Jun 24, 2013 · Synced Oct 13, 2026, 6:42 PM EDT
Completed Phase 3 Interventional Results available

Warfarin Versus Aspirin in Reduced Cardiac Ejection Fraction (WARCEF) Trial

NCT00041938
View directory record Official record
Conditions
Heart Disease, Stroke, Ischemic Heart Disease, Myocardial Infarction
Interventions
aspirin, Warfarin
Drug
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Enrollment
2,305 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2014
U.S. locations
54
States / cities
Tucson, Arizona • Santa Clara, California • West Los Angeles, California + 41 more
Source: ClinicalTrials.gov public record
Updated Sep 5, 2014 · Synced Oct 13, 2026, 6:42 PM EDT
Completed Phase 2 Interventional

Safety and Efficacy of TAK-442 in Subjects With Acute Coronary Syndromes

NCT00677053
View directory record Official record
Conditions
Acute Coronary Syndrome
Interventions
TAK-442, Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
30 Years to 80 Years
Enrollment
2,753 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
15
States / cities
Birmingham, Alabama • Tucson, Arizona • Newark, Delaware + 12 more
Source: ClinicalTrials.gov public record
Updated Apr 13, 2016 · Synced Oct 13, 2026, 6:42 PM EDT
Not yet recruiting Phase 4 Interventional

Extended Prophylactic Anticoagulation Following Spinal Surgery for Metastatic Disease

NCT07713875
View directory record Official record
Conditions
Venous Thromboembolism (VTE), Deep Vein Thrombosis (DVT), Pulmonary Embolism (PE), Spine Metastasis
Interventions
Apixaban
Drug
Lead sponsor
James Bayley
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
3
States / cities
Pittburgh, Pennsylvania • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 20, 2026 · Synced Oct 13, 2026, 6:42 PM EDT
Completed No phase listed Observational

Global Anticoagulant Registry in the FIELD- Venous Thromboembolic Events

NCT02155491
View directory record Official record
Conditions
Venous Thromboembolism, Deep Vein Thrombosis, Pulmonary Embolism
Interventions
Not listed
Lead sponsor
Thrombosis Research Institute
Other
Eligibility
18 Years to 99 Years
Enrollment
10,679 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
1
States / cities
Muscle Shoals, Alabama
Source: ClinicalTrials.gov public record
Updated May 5, 2021 · Synced Oct 13, 2026, 6:42 PM EDT